Lynne Ai Bui, MD
Hematology/Oncology · Crescent City
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 35
- 10 carriers
- Offices
- 5
Offices
5 locations · Sutter Coast Hospital · Phc-Las Cruces Inc · Las Cruces Physician Practices, LLC
Looking this up.
Hospitals listed: Good Samaritan Hospital · Hazel Hawkins Memorial Hospital · Memorial Medical Center · Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
35 plans · 10 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bui’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
35 of 35 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Kaiser Permanente Dual Complete North P2 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Dual Complete North P23 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Basic Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Enhanced Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A66600 · Current
Licensed to practise in California · since 1998 · expires 2028-07-31 · University of California, Los Angeles School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Hazel Hawkins Memorial HospitalHollister, CACritical Access Hospital · Government - Hospital District or Authority · Has an emergency departmentNo overall ratingNo measure marked better or worse than the national rate
- Memorial Medical CenterLas Cruces, NMAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Lifepoint Health, which runs 79 hospitals in 21 statesPatients rate it 2 of 5 · 63% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Postoperative respiratory failure rate: 17.52 (10.16 to 24.88) · 263 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.234, Oct 2024 – Sep 2025
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Hazel Hawkins Memorial Hospital
Behind the star rating — Readmissions: 0 better, 2 the same, 0 worse of 2 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.6 to 17.1) · 409 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 43 cases | No different | Jan 2024 – Dec 2024 |
See every measure and the patient survey for Memorial Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 3 better, 3 the same, 0 worse of 6 measures. Readmissions: 0 better, 7 the same, 3 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative respiratory failure rateComplications and deaths | 17.52 (10.16 to 24.88) · 263 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.234 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.9 (0 to 1.91) · 704 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.18 (0.81 to 1.54) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 177.67 (125.68 to 229.66) · 42 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 36 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.1 · 58 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.3 · 145 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.9 · 169 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.7 · 155 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.9 · 1,977 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 3,164 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 3,325 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.5 (0.26 to 4.73) · 868 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.68 (1.07 to 4.3) · 255 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.32 (0.8 to 3.85) · 846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.66 (1.8 to 9.52) · 257 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.69 (0.19 to 3.19) · 145 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0 to 1.35) · 2,596 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.244 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.408 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.448 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.2 · 207 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23.3 · 265 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 27.7 · 131 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 35.8 · 178 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 40.6 · 157 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 257 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.3 to 7.3) · 135 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.5 (8.4 to 15.6) · 135 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 10.6 · 48 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 105 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (9.8 to 18) · 211 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 411 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,078 patients answered, 19% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 73% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 77% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 70% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 62% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 63% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$762,690
Medicare paid this office $762,690 for 253 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 244 | $126,420 | $116 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 16 | $46,260 | None |
| Injection, denosumab, 1 mg | 21 | $41,893 | None |
| Administration of chemotherapy into vein, 1 hour or less | 20 | $20,656 | $140 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 31 | $11,967 | $66 |
See all 25 services
| Return visit (30+ min) | 244 | $126,420 | $116 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 16 | $46,260 | None |
| Injection, denosumab, 1 mg | 21 | $41,893 | None |
| Administration of chemotherapy into vein, 1 hour or less | 20 | $20,656 | $140 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 31 | $11,967 | $66 |
| New patient visit (60+ min) | 56 | $11,412 | $204 |
| Short return visit (20+ min) | 42 | $10,402 | $78 |
| Infusion into a vein for hydration, 31-60 minutes | 34 | $7,103 | $34 |
| Injection of drug or substance under skin or into muscle | 57 | $5,975 | $13 |
| Injection of drug or substance into vein | 18 | $5,389 | $39 |
| Administration of chemotherapy into vein, each additional hour | 11 | $5,167 | $29 |
| Drawing of blood for a medical problem | 12 | $3,495 | $100 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 28 | $3,151 | $20 |
| Infusion into a vein for hydration, each additional hour | 15 | $2,890 | $13 |
| Long return visit (40+ min) | 12 | $2,166 | $167 |
| Injection, dexamethasone sodium phosphate, 1 mg | 24 | $223 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 20 | $175 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 24 | $152 | None |
| Infusion, normal saline solution, 250 cc | 43 | $151 | None |
| Insertion of needle into vein for collection of blood sample | 11 | $103 | $5 |
| Injection, diphenhydramine hcl, up to 50 mg | 25 | $103 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 18 | $95 | None |
| 5% dextrose/water (500 ml = 1 unit) | 14 | $84 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 23 | $73 | None |
| Unclassified drugs | 20 | $39 | None |
Who their Medicare patients are
253 Original Medicare patients in 2024. Average age 76 · Women 63% · Also on Medicaid 36% · Health risk score 1.67. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Diabetes 45% · Cancer 42% · Chronic kidney disease 28% · Coronary heart disease 26% · Depression 23% · Heart failure 21% · COPD 19% · Atrial fibrillation 15% · Stroke 14% · Dementia 9%.
The office billed $2,175,716, Medicare allowed $967,501 and paid $762,690; for 80,283 services of 65 kinds; $525,516 of it was for drugs given in the office and $237,174 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 253 | 80,283 | 76 | 1.67 | $2,175,716 | $762,690 |
| 2023 | 276 | 59,560 | 76 | 1.73 | $1,401,855 | $689,588 |
| 2022 | 300 | 112,285 | 76 | 1.77 | $4,184,543 | $2,161,464 |
| 2021 | 347 | 153,926 | 76 | 1.70 | $5,313,719 | $2,828,819 |
| 2020 | 360 | 198,239 | 75 | 1.78 | $5,973,014 | $2,878,090 |
| 2019 | 429 | 181,726 | 75 | 1.87 | $6,783,035 | $2,744,612 |
| 2018 | 427 | 263,996 | 74 | 1.82 | $7,341,968 | $2,774,123 |
| 2017 | 338 | 281,929 | 76 | 1.97 | $8,610,158 | $3,002,990 |
| 2016 | 350 | 234,927 | 76 | 1.89 | $8,196,756 | $2,813,599 |
| 2015 | 352 | 128,763 | 75 | 1.93 | $5,145,774 | $1,970,749 |
| 2014 | 292 | 22,090 | 75 | 1.64 | $1,438,649 | $569,910 |
| 2013 | 203 | 11,447 | 74 | 1.15 | $620,935 | $282,320 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 25 services
| Return visit (30+ min) | 261 | $86,664 | $90 |
| Insertion of needle or tube into artery of arm or leg | 37 | $58,029 | $547 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 14 | $34,488 | None |
| Injection, denosumab, 1 mg | 20 | $31,746 | None |
| Short return visit (20+ min) | 79 | $25,332 | $83 |
| Injection, ferric carboxymaltose, 1 mg | 17 | $22,168 | None |
| New patient visit (60+ min) | 52 | $10,402 | $200 |
| Administration of chemotherapy into vein, 1 hour or less | 19 | $8,844 | $140 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 32 | $6,184 | $69 |
| Injection of drug or substance under skin or into muscle | 72 | $6,025 | $14 |
| Drawing of blood for a medical problem | 14 | $5,772 | $105 |
| Long return visit (40+ min) | 21 | $4,207 | $131 |
| Infusion into a vein for hydration, 31-60 minutes | 37 | $3,706 | $35 |
| Injection of drug or substance into vein | 11 | $1,897 | $40 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 27 | $1,539 | $20 |
| Infusion into a vein for hydration, each additional hour | 13 | $872 | $13 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 11 | $546 | $30 |
| Insertion of needle into vein for collection of blood sample | 14 | $250 | $5 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 31 | $226 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 29 | $129 | None |
| Infusion, normal saline solution, 250 cc | 46 | $90 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 23 | $88 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 31 | $72 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 16 | $63 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 12 | $57 | None |
2022: 25 services
| Insertion of needle or tube into artery of arm or leg | 44 | $153,874 | $570 |
| Return visit (30+ min) | 271 | $113,027 | $102 |
| Injection, denosumab, 1 mg | 31 | $107,570 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 19 | $66,870 | None |
| Injection, ferric carboxymaltose, 1 mg | 19 | $28,728 | None |
| Short return visit (20+ min) | 87 | $28,259 | $82 |
| Administration of chemotherapy into vein, 1 hour or less | 22 | $23,583 | $147 |
| Long return visit (40+ min) | 45 | $20,814 | $158 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 44 | $15,003 | $72 |
| New patient visit (60+ min) | 63 | $11,948 | $190 |
| Infusion into a vein for hydration, 31-60 minutes | 44 | $9,633 | $36 |
| Injection of drug or substance under skin or into muscle | 83 | $8,652 | $14 |
| Drawing of blood for a medical problem | 14 | $5,692 | $107 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 44 | $4,292 | $21 |
| Injection of drug or substance into vein | 15 | $3,178 | $42 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 20 | $1,293 | $30 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 33 | $262 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 37 | $242 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 40 | $167 | None |
| Insertion of needle into vein for collection of blood sample | 14 | $157 | $3 |
| Infusion, normal saline solution, 250 cc | 40 | $155 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 16 | $111 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 16 | $108 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 30 | $78 | None |
| 5% dextrose/water (500 ml = 1 unit) | 12 | $64 | None |
2021: 29 services
| Insertion of needle or tube into artery of arm or leg | 50 | $215,343 | $570 |
| Injection, denosumab, 1 mg | 39 | $135,801 | None |
| Return visit (30+ min) | 274 | $128,811 | $120 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 34 | $106,952 | None |
| Injection, ferric carboxymaltose, 1 mg | 27 | $51,927 | None |
| Short return visit (20+ min) | 127 | $47,290 | $88 |
| Long return visit (40+ min) | 81 | $41,792 | $170 |
| Administration of chemotherapy into vein, 1 hour or less | 17 | $31,789 | $158 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 47 | $23,357 | $79 |
| New patient visit (60+ min) | 78 | $16,235 | $208 |
| Infusion into a vein for hydration, 31-60 minutes | 50 | $14,362 | $38 |
| Injection of drug or substance under skin or into muscle | 101 | $11,411 | $14 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $8,134 | $95 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 44 | $6,328 | $22 |
| Drawing of blood for a medical problem | 12 | $4,590 | $118 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 31 | $3,351 | $34 |
| Injection of drug or substance into vein | 12 | $2,487 | $44 |
| Infusion into a vein for hydration, each additional hour | 20 | $2,021 | $14 |
| Injection, ranitidine hydrochloride, 25 mg | 17 | $1,155 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 40 | $475 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 30 | $308 | None |
| Infusion, normal saline solution, 250 cc | 47 | $241 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 41 | $189 | None |
| Infusion, normal saline solution , 1000 cc | 11 | $173 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 14 | $162 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 14 | $152 | None |
| 5% dextrose/water (500 ml = 1 unit) | 13 | $119 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 33 | $117 | None |
| Insertion of needle into vein for collection of blood sample | 12 | $117 | $3 |
2020: 28 services
| Insertion of needle or tube into artery of arm or leg | 54 | $228,166 | $514 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 34 | $163,598 | None |
| Injection, denosumab, 1 mg | 38 | $160,183 | None |
| Return visit (30+ min) | 284 | $97,600 | $97 |
| Short return visit (20+ min) | 115 | $60,072 | $70 |
| Long return visit (40+ min) | 107 | $46,258 | $135 |
| Injection, ferric carboxymaltose, 1 mg | 20 | $31,085 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 50 | $22,718 | $75 |
| Administration of chemotherapy into vein, 1 hour or less | 26 | $21,251 | $151 |
| Infusion into a vein for hydration, 31-60 minutes | 54 | $15,825 | $36 |
| Injection of drug or substance under skin or into muscle | 103 | $13,150 | $14 |
| New patient visit (60+ min) | 74 | $12,895 | $174 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $8,108 | $97 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 46 | $5,528 | $22 |
| Drawing of blood for a medical problem | 13 | $5,255 | $103 |
| Administration of chemotherapy into vein, each additional hour | 14 | $4,076 | $31 |
| Infusion into a vein for hydration, each additional hour | 33 | $3,721 | $14 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 26 | $3,505 | $32 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 41 | $1,234 | None |
| Injection, ranitidine hydrochloride, 25 mg | 25 | $915 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 42 | $314 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 24 | $240 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 24 | $212 | None |
| 5% dextrose/water (500 ml = 1 unit) | 26 | $181 | None |
| Infusion, normal saline solution, 250 cc | 46 | $180 | None |
| Insertion of needle into vein for collection of blood sample | 14 | $155 | $3 |
| Injection, diphenhydramine hcl, up to 50 mg | 45 | $146 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 22 | $138 | None |
2019: 31 services
| Insertion of needle or tube into artery of arm or leg | 64 | $241,087 | $465 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 42 | $180,634 | None |
| Injection, denosumab, 1 mg | 49 | $173,389 | None |
| Return visit (30+ min) | 314 | $73,607 | $99 |
| Short return visit (20+ min) | 145 | $71,536 | $70 |
| Long return visit (40+ min) | 185 | $63,663 | $135 |
| Administration of chemotherapy into vein, 1 hour or less | 33 | $33,410 | $148 |
| Injection, ferric carboxymaltose, 1 mg | 19 | $26,215 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 59 | $25,181 | $75 |
| New patient visit (60+ min) | 122 | $22,613 | $185 |
| Infusion into a vein for hydration, 31-60 minutes | 64 | $20,251 | $39 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 36 | $17,404 | $83 |
| Injection of drug or substance under skin or into muscle | 116 | $13,522 | $16 |
| Administration of additional new drug or substance into vein, 1 hour or less | 16 | $8,578 | $71 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $6,782 | $92 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 54 | $6,183 | $21 |
| Drawing of blood for a medical problem | 15 | $5,665 | $107 |
| Infusion into a vein for hydration, each additional hour | 39 | $5,143 | $14 |
| Administration of chemotherapy into vein, each additional hour | 16 | $4,706 | $31 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 25 | $2,284 | $32 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 41 | $1,562 | None |
| Injection of drug or substance into vein | 13 | $1,247 | $40 |
| Injection, ranitidine hydrochloride, 25 mg | 32 | $914 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 53 | $383 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 46 | $329 | None |
| 5% dextrose/water (500 ml = 1 unit) | 25 | $284 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 30 | $276 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 24 | $237 | None |
| Infusion, normal saline solution, 250 cc | 58 | $202 | None |
| Insertion of needle into vein for collection of blood sample | 23 | $171 | $3 |
| Injection, diphenhydramine hcl, up to 50 mg | 50 | $137 | None |
2018: 35 services
| Insertion of needle or tube into artery of arm or leg | 72 | $284,343 | $440 |
| Injection, pegfilgrastim, 6 mg | 17 | $227,892 | None |
| Injection, denosumab, 1 mg | 51 | $225,854 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 50 | $211,453 | None |
| Return visit (30+ min) | 332 | $110,922 | $101 |
| Short return visit (20+ min) | 180 | $88,287 | $68 |
| Long return visit (40+ min) | 173 | $53,300 | $134 |
| Injection, ferric carboxymaltose, 1 mg | 35 | $50,017 | None |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 66 | $39,273 | $84 |
| Administration of chemotherapy into vein, 1 hour or less | 40 | $38,370 | $149 |
| Infusion into a vein for hydration, 31-60 minutes | 91 | $36,484 | $48 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 80 | $35,031 | $75 |
| Administration of prolonged chemotherapy into vein | 34 | $28,367 | $153 |
| New patient visit (60+ min) | 149 | $28,340 | $190 |
| Injection of drug or substance under skin or into muscle | 109 | $18,738 | $20 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 14 | $18,398 | None |
| Infusion into a vein for hydration, each additional hour | 85 | $15,306 | $14 |
| Administration of additional new drug or substance into vein, 1 hour or less | 37 | $15,136 | $71 |
| Injection of drug or substance into vein | 52 | $14,875 | $48 |
| Administration of chemotherapy into vein, each additional hour | 35 | $13,919 | $32 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 64 | $11,200 | $22 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $10,888 | $93 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 67 | $6,560 | $21 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 24 | $1,504 | $32 |
| Injection, ranitidine hydrochloride, 25 mg | 45 | $1,156 | None |
| 5% dextrose/water (500 ml = 1 unit) | 66 | $1,032 | None |
| Injection, carboplatin, 50 mg | 11 | $865 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 64 | $605 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 16 | $597 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 73 | $580 | None |
| Infusion, normal saline solution , 1000 cc | 26 | $516 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 53 | $481 | None |
| Infusion, normal saline solution, 250 cc | 78 | $479 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 59 | $408 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 75 | $180 | None |
2017: 37 services
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 56 | $269,013 | None |
| Injection, pegfilgrastim, 6 mg | 12 | $208,821 | None |
| Injection, denosumab, 1 mg | 41 | $196,703 | None |
| Insertion of needle or tube into artery of arm or leg | 40 | $159,021 | $433 |
| Return visit (30+ min) | 254 | $96,623 | $100 |
| Short return visit (20+ min) | 139 | $79,264 | $69 |
| Injection, ferric carboxymaltose, 1 mg | 37 | $58,881 | None |
| Long return visit (40+ min) | 203 | $58,406 | $130 |
| Administration of prolonged chemotherapy into vein | 35 | $54,735 | $146 |
| Administration of chemotherapy into vein, 1 hour or less | 35 | $54,156 | $144 |
| Infusion into a vein for hydration, 31-60 minutes | 94 | $47,236 | $59 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 86 | $43,095 | $71 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 60 | $36,463 | $77 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 16 | $30,406 | None |
| Administration of chemotherapy into vein, each additional hour | 35 | $29,371 | $28 |
| Administration of additional new drug or substance into vein, 1 hour or less | 35 | $25,309 | $67 |
| Infusion into a vein for hydration, each additional hour | 94 | $25,021 | $15 |
| Injection of drug or substance into vein | 41 | $24,496 | $59 |
| Injection of drug or substance under skin or into muscle | 92 | $24,436 | $26 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 86 | $24,185 | $19 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $14,358 | $93 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 86 | $12,573 | $21 |
| New patient visit (60+ min) | 66 | $12,434 | $188 |
| Short return visit | 36 | $2,794 | $42 |
| Harvesting of donor bone marrow for transplantation | 12 | $2,002 | $167 |
| Injection, iron sucrose, 1 mg | 12 | $1,943 | None |
| 5% dextrose/water (500 ml = 1 unit) | 93 | $1,906 | None |
| Biopsy of bone marrow | 17 | $1,544 | $86 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 73 | $1,273 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 82 | $858 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 48 | $797 | None |
| Injection, ranitidine hydrochloride, 25 mg | 45 | $785 | None |
| Infusion, normal saline solution, 250 cc | 75 | $738 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 82 | $668 | None |
| Infusion, normal saline solution , 1000 cc | 24 | $575 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 50 | $549 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 82 | $291 | None |
2016: 40 services
| Injection, rituximab, 100 mg | 14 | $318,193 | None |
| Insertion of needle or tube into artery of arm or leg | 63 | $252,900 | $447 |
| Injection, pegfilgrastim, 6 mg | 16 | $175,884 | None |
| Injection, denosumab, 1 mg | 45 | $149,568 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 45 | $140,225 | None |
| Return visit (30+ min) | 281 | $89,923 | $97 |
| Administration of prolonged chemotherapy into vein | 48 | $76,569 | $146 |
| Administration of chemotherapy into vein, 1 hour or less | 48 | $74,023 | $140 |
| Long return visit (40+ min) | 178 | $48,351 | $132 |
| Infusion into a vein for hydration, 31-60 minutes | 87 | $44,881 | $59 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 78 | $44,546 | $71 |
| Short return visit (20+ min) | 136 | $42,540 | $68 |
| Injection, ferric carboxymaltose, 1 mg | 18 | $36,272 | None |
| Leuprolide acetate (for depot suspension), 7.5 mg | 18 | $33,690 | None |
| Administration of chemotherapy into vein, each additional hour | 48 | $30,069 | $28 |
| Injection of drug or substance into vein | 63 | $28,779 | $58 |
| Administration of additional new drug or substance into vein, 1 hour or less | 48 | $27,443 | $64 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 45 | $22,743 | $77 |
| Infusion into a vein for hydration, each additional hour | 86 | $22,308 | $15 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 76 | $21,078 | $18 |
| New patient visit (60+ min) | 107 | $19,753 | $185 |
| Injection of drug or substance under skin or into muscle | 97 | $13,403 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 72 | $12,401 | $20 |
| Short return visit | 79 | $10,564 | $41 |
| Refilling and maintenance of portable pump | 23 | $9,342 | $144 |
| Administration of chemotherapy into vein using push technique | 17 | $3,775 | $114 |
| Drawing of blood for a medical problem | 12 | $3,436 | $104 |
| Biopsy of bone marrow | 20 | $3,270 | $163 |
| Injection, paclitaxel, 1 mg | 13 | $1,856 | None |
| 5% dextrose/water (500 ml = 1 unit) | 77 | $1,655 | None |
| Aspiration of bone marrow sample for diagnosis | 13 | $1,075 | $83 |
| Injection, dexamethasone sodium phosphate, 1 mg | 67 | $1,001 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 79 | $902 | None |
| Infusion, normal saline solution, 250 cc | 95 | $729 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 66 | $721 | None |
| Infusion, normal saline solution , 1000 cc | 46 | $459 | None |
| Injection, ranitidine hydrochloride, 25 mg | 46 | $420 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 78 | $295 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 25 | $282 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 63 | $238 | None |
2015: 44 services
| Injection, pegfilgrastim, 6 mg | 22 | $221,290 | None |
| Injection, rituximab, 100 mg | 12 | $209,030 | None |
| Insertion of needle or tube into artery of arm or leg | 48 | $129,972 | $418 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 33 | $95,082 | None |
| Injection, denosumab, 1 mg | 25 | $62,093 | None |
| Return visit (30+ min) | 254 | $61,595 | $96 |
| Administration of chemotherapy into vein, 1 hour or less | 50 | $53,605 | $133 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 79 | $32,219 | $67 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 18 | $31,660 | None |
| Short return visit (20+ min) | 229 | $30,077 | $61 |
| Administration of prolonged chemotherapy into vein | 30 | $26,133 | $139 |
| Infusion into a vein for hydration, 31-60 minutes | 76 | $23,256 | $56 |
| Long return visit (40+ min) | 100 | $20,015 | $130 |
| Injection, ferric carboxymaltose, 1 mg | 14 | $18,828 | None |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 23 | $12,230 | $75 |
| Infusion into a vein for hydration, each additional hour | 69 | $11,848 | $15 |
| Injection of drug or substance into vein | 51 | $11,051 | $56 |
| Administration of chemotherapy into vein, each additional hour | 41 | $10,261 | $28 |
| New patient visit (60+ min) | 52 | $9,648 | $186 |
| Administration of chemotherapy into vein using push technique | 19 | $9,262 | $110 |
| Injection of drug or substance under skin or into muscle | 83 | $8,966 | $24 |
| Administration of additional new drug or substance into vein, 1 hour or less | 33 | $8,562 | $62 |
| Injection, zoledronic acid, 1 mg | 19 | $7,597 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 40 | $6,957 | $30 |
| Short return visit | 60 | $6,701 | $41 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 51 | $5,633 | $18 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 46 | $4,290 | $20 |
| Drawing of blood for a medical problem | 14 | $4,109 | $96 |
| New patient visit (45+ min) | 26 | $3,535 | $136 |
| Administration of additional new drug or substance into vein using push technique | 16 | $3,391 | $59 |
| Biopsy of bone marrow | 12 | $1,878 | $157 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 30 | $801 | $18 |
| Irrigation of implanted venous access drug delivery device | 11 | $701 | $24 |
| Injection, dexamethasone sodium phosphate, 1 mg | 51 | $584 | None |
| 5% dextrose/water (500 ml = 1 unit) | 67 | $550 | None |
| Infusion, normal saline solution, 250 cc | 89 | $431 | None |
| Infusion, normal saline solution , 1000 cc | 53 | $421 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 73 | $332 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 40 | $279 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 67 | $176 | None |
| Injection, ranitidine hydrochloride, 25 mg | 25 | $161 | None |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 11 | $127 | $12 |
| Injection, diphenhydramine hcl, up to 50 mg | 39 | $70 | None |
| Injection, lidocaine hcl for intravenous infusion, 10 mg | 12 | $1 | None |
2014: 29 services
| Injection, pegfilgrastim, 6 mg | 20 | $130,883 | None |
| Return visit (30+ min) | 211 | $30,504 | $90 |
| Injection, denosumab, 1 mg | 11 | $15,483 | None |
| Administration of chemotherapy into vein, 1 hour or less | 45 | $13,683 | $133 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 50 | $9,862 | $68 |
| Infusion into a vein for hydration, 31-60 minutes | 48 | $8,443 | $58 |
| New patient visit (60+ min) | 43 | $8,101 | $188 |
| Injection, zoledronic acid, 1 mg | 20 | $5,472 | None |
| Short return visit (20+ min) | 60 | $5,387 | $67 |
| Insertion of artery tube for prolonged infusion | 30 | $5,257 | $114 |
| New patient visit (45+ min) | 27 | $3,983 | $148 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $3,867 | $73 |
| Long return visit (40+ min) | 12 | $2,892 | $131 |
| Administration of chemotherapy into vein, each additional hour | 27 | $2,749 | $28 |
| Drawing of blood for a medical problem | 12 | $2,448 | $91 |
| Infusion into a vein for hydration, each additional hour | 31 | $2,060 | $15 |
| Short return visit | 26 | $1,737 | $39 |
| Injection of drug or substance into vein | 15 | $1,600 | $57 |
| Injection of drug or substance under skin or into muscle | 33 | $1,455 | $22 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 19 | $1,172 | $30 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 28 | $910 | $19 |
| 5% dextrose/water (500 ml = 1 unit) | 37 | $126 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 29 | $97 | None |
| Infusion, normal saline solution, 250 cc | 58 | $65 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 30 | $64 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 39 | $58 | None |
| 5% dextrose/normal saline (500 ml = 1 unit) | 22 | $49 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 21 | $48 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 14 | $14 | None |
2013: 17 services
| Injection, infliximab, excludes biosimilar, 10 mg | 16 | $85,936 | None |
| Return visit (30+ min) | 171 | $30,203 | $99 |
| Injection, denosumab, 1 mg | 26 | $17,310 | None |
| Administration of chemotherapy into vein, 1 hour or less | 25 | $10,051 | $146 |
| Insertion of needle or tube into artery of arm or leg | 14 | $7,498 | $441 |
| Insertion of artery tube for prolonged infusion | 34 | $7,288 | $116 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 18 | $4,238 | $77 |
| Injection of drug or substance under skin or into muscle | 57 | $3,728 | $26 |
| New patient visit (45+ min) | 23 | $3,351 | $146 |
| Administration of chemotherapy into vein, each additional hour | 19 | $3,026 | $31 |
| Aspiration and/or injection of fluid from large joint | 24 | $2,769 | $49 |
| Aspiration and/or injection of fluid from medium joint | 11 | $668 | $56 |
| Injection, triamcinolone hexacetonide, per 5 mg | 30 | $172 | None |
| Injection, methotrexate sodium, 50 mg | 14 | $165 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 30 | $118 | None |
| Injection, methylprednisolone acetate, 40 mg | 12 | $46 | None |
| Infusion, normal saline solution, 250 cc | 37 | $27 | None |
Medicaid work
$4,443 in 2024
Medicaid paid $4,443 for 854 billed services this clinician did in 2024, up to 56 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 673 | $4,033 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 149 | $302 |
| Short return visit (20+ min) | 32 | $108 |
| 2024 | 854 | 3 | 56 | $4,443 |
| 2023 | 930 | 4 | 55 | $8,826 |
| 2022 | 1,228 | 11 | 45 | $9,803 |
| 2021 | 1,431 | 8 | 36 | $8,562 |
| 2020 | 1,324 | 13 | 32 | $11,362 |
| 2019 | 1,447 | 16 | 38 | $15,535 |
| 2018 | 1,650 | 23 | 35 | $17,217 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 609 | $7,648 |
| Short return visit (20+ min) | 99 | $747 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 166 | $409 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 56 | $21 |
2022
| Return visit (30+ min) | 513 | $6,053 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 229 | $1,437 |
| Short return visit (20+ min) | 121 | $748 |
| Injection, dexamethasone sodium phosphate, 1 mg | 102 | $514 |
| Injection, diphenhydramine hcl, up to 50 mg | 106 | $430 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 15 | $319 |
| Long return visit (40+ min) | 18 | $120 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure) | 25 | $92 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 22 | $41 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 51 | $26 |
| Infusion, normal saline solution, 250 cc | 26 | $22 |
2021
| Return visit (30+ min) | 670 | $5,572 |
| Short return visit (20+ min) | 203 | $981 |
| Injection, diphenhydramine hcl, up to 50 mg | 197 | $689 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 223 | $653 |
| Injection, dexamethasone sodium phosphate, 1 mg | 76 | $285 |
| Long return visit (40+ min) | 29 | $258 |
| Injection, ranitidine hydrochloride, 25 mg | 20 | $105 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 13 | $20 |
2020
| Return visit (30+ min) | 390 | $5,384 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 58 | $1,146 |
| Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 73 | $1,099 |
| Injection, diphenhydramine hcl, up to 50 mg | 246 | $1,045 |
| Injection, dexamethasone sodium phosphate, 1 mg | 145 | $648 |
| Injection, ondansetron hydrochloride, per 1 mg | 108 | $605 |
| Long return visit (40+ min) | 74 | $594 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure) | 58 | $347 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 41 | $166 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 69 | $155 |
| Injection, ranitidine hydrochloride, 25 mg | 26 | $77 |
| Short return visit (20+ min) | 17 | $70 |
2019
| Return visit (30+ min) | 409 | $6,505 |
| Long return visit (40+ min) | 110 | $2,994 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 133 | $1,754 |
| Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 86 | $936 |
| Short return visit (20+ min) | 175 | $825 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 57 | $726 |
| Injection, diphenhydramine hcl, up to 50 mg | 143 | $546 |
| Injection, dexamethasone sodium phosphate, 1 mg | 120 | $516 |
| Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure) | 27 | $163 |
| Injection, ranitidine hydrochloride, 25 mg | 44 | $158 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure) | 38 | $127 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 20 | $112 |
2018
| Return visit (30+ min) | 499 | $8,982 |
| Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 154 | $2,690 |
| Short return visit (20+ min) | 173 | $1,600 |
| Long return visit (40+ min) | 45 | $1,098 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 37 | $657 |
| Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure) | 76 | $520 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 45 | $411 |
| Injection, dexamethasone sodium phosphate, 1 mg | 103 | $328 |
| Injection, diphenhydramine hcl, up to 50 mg | 105 | $268 |
| Injection, ondansetron hydrochloride, per 1 mg | 54 | $181 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 62 | $154 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 15 | $103 |
Drugs they prescribed that Part D paid
$836,745
Pharmacies billed $836,745 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
86 generic and 62 brand-name prescriptions · $836,745 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ibrance | 23 | $372,315 | $16,188 |
| Acyclovir | 15 | $249 | $17 |
| Allopurinol | 15 | $128 | $9 |
Year by year
| 2024 | 148 | 37 | None | 42% | $836,745 |
| 2023 | 201 | 61 | None | None | $626,189 |
| 2022 | 148 | 38 | None | 43% | $926,593 |
| 2021 | 333 | 83 | None | 39% | $1,471,186 |
| 2020 | 562 | 120 | 2% (13) | 43% | $1,687,923 |
| 2019 | 529 | 99 | None | 54% | $1,466,041 |
| 2018 | 997 | 145 | 2% (23) | 42% | $2,638,472 |
| 2017 | 911 | 127 | 7% (63) | 23% | $1,739,989 |
| 2016 | 785 | 118 | 8% (59) | 24% | $1,259,454 |
| 2015 | 935 | 121 | 18% (171) | 19% | $878,273 |
| 2014 | 310 | 70 | 29% (89) | None | $254,147 |
| 2013 | 41 | None | 0% (0) | None | $17,635 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Ibrance | 19 | $317,486 | $16,710 |
| Eliquis | 20 | $13,436 | $672 |
| Imatinib Mesylate | 12 | $6,320 | $527 |
| Anastrozole | 33 | $1,051 | $32 |
| Hydroxyurea | 19 | $844 | $44 |
2022: 3 drugs
| Ibrance | 20 | $306,459 | $15,323 |
| Revlimid | 14 | $278,648 | $19,903 |
| Anastrozole | 11 | $520 | $47 |
2021: 9 drugs
| Ibrance | 22 | $323,868 | $14,721 |
| Cabometyx | 11 | $243,935 | $22,176 |
| Revlimid | 11 | $238,859 | $21,714 |
| Erlotinib | 11 | $64,613 | $5,874 |
| Procrit | 13 | $58,019 | $4,463 |
| Imatinib Mesylate | 11 | $46,011 | $4,183 |
| Retacrit | 11 | $20,383 | $1,853 |
| Letrozole | 23 | $954 | $41 |
| Anastrozole | 22 | $883 | $40 |
2020: 17 drugs
| Tagrisso | 18 | $294,667 | $16,370 |
| Xtandi | 19 | $247,107 | $13,006 |
| Cabometyx | 11 | $227,092 | $20,645 |
| Procrit | 29 | $127,047 | $4,381 |
| Xgeva | 29 | $70,169 | $2,420 |
| Erlotinib | 11 | $67,486 | $6,135 |
| Imatinib Mesylate | 11 | $52,407 | $4,764 |
| Retacrit | 22 | $40,153 | $1,825 |
| Nplate | 19 | $38,836 | $2,044 |
| Prolia | 22 | $28,845 | $1,311 |
| Xarelto | 11 | $9,225 | $839 |
| Exemestane | 12 | $3,499 | $292 |
| Anastrozole | 91 | $2,128 | $23 |
| Hydroxyurea | 26 | $1,747 | $67 |
| Letrozole | 34 | $1,576 | $46 |
| Dexamethasone | 12 | $346 | $29 |
| Ondansetron | 11 | $175 | $16 |
2019: 14 drugs
| Ibrance | 24 | $284,014 | $11,834 |
| Procrit | 64 | $273,765 | $4,278 |
| Tagrisso | 12 | $185,286 | $15,441 |
| Xgeva | 59 | $132,486 | $2,246 |
| Imatinib Mesylate | 24 | $91,522 | $3,813 |
| Neulasta | 11 | $65,767 | $5,979 |
| Prolia | 33 | $41,256 | $1,250 |
| Nplate | 20 | $38,271 | $1,914 |
| Faslodex | 14 | $25,662 | $1,833 |
| Exemestane | 16 | $5,056 | $316 |
| Hydroxyurea | 34 | $2,217 | $65 |
| Anastrozole | 88 | $1,931 | $22 |
| Letrozole | 28 | $828 | $30 |
| Tamoxifen Citrate | 11 | $684 | $62 |
2018: 25 drugs
| Ibrance | 47 | $530,904 | $11,296 |
| Procrit | 62 | $258,966 | $4,177 |
| Xtandi | 21 | $238,471 | $11,356 |
| Xgeva | 91 | $205,003 | $2,253 |
| Revlimid | 14 | $157,133 | $11,224 |
| Jakafi | 13 | $131,344 | $10,103 |
| Tarceva | 13 | $117,080 | $9,006 |
| Neulasta | 18 | $111,055 | $6,170 |
| Imatinib Mesylate | 12 | $81,337 | $6,778 |
| Prolia | 32 | $38,996 | $1,219 |
| Nplate | 11 | $20,466 | $1,861 |
| Exemestane | 29 | $11,600 | $400 |
| Hydroxyurea | 55 | $2,506 | $46 |
| Anastrozole | 149 | $2,183 | $15 |
| Letrozole | 72 | $1,353 | $19 |
| Tamoxifen Citrate | 24 | $1,000 | $42 |
| Doxycycline Hyclate | 19 | $386 | $20 |
| Bicalutamide | 17 | $363 | $21 |
| Warfarin | 17 | $264 | $16 |
| Ondansetron Odt | 14 | $238 | $17 |
| Levothyroxine | 11 | $231 | $21 |
| Pantoprazole | 12 | $224 | $19 |
| Mirtazapine | 13 | $182 | $14 |
| Jantoven | 11 | $82 | $7 |
| Lactulose | 13 | $55 | $4 |
2017: 24 drugs
| Ibrance | 41 | $462,592 | $11,283 |
| Xtandi | 21 | $175,307 | $8,348 |
| Revlimid | 12 | $153,287 | $12,774 |
| Gleevec | 12 | $143,793 | $11,983 |
| Procrit | 26 | $102,685 | $3,949 |
| Jakafi | 12 | $94,321 | $7,860 |
| Exemestane | 57 | $19,208 | $337 |
| Anastrozole | 183 | $2,196 | $12 |
| Hydroxyurea | 48 | $1,658 | $35 |
| Letrozole | 82 | $965 | $12 |
| Tamoxifen Citrate | 16 | $791 | $49 |
| Morphine Sulfate Er | 14 | $546 | $39 |
| Oxycodone | 19 | $483 | $25 |
| Bicalutamide | 26 | $459 | $18 |
| Ondansetron Odt | 21 | $403 | $19 |
| Doxycycline Hyclate | 15 | $386 | $26 |
| Hydrocodone-Acetaminophen | 18 | $378 | $21 |
| Dexamethasone | 29 | $351 | $12 |
| Omeprazole | 29 | $280 | $10 |
| Levothyroxine | 12 | $274 | $23 |
| Prednisone | 20 | $160 | $8 |
| Warfarin | 14 | $123 | $9 |
| Ondansetron | 12 | $98 | $8 |
| Lorazepam | 13 | $18 | $1 |
2016: 16 drugs
| Xtandi | 33 | $222,587 | $6,745 |
| Ibrance | 18 | $188,936 | $10,496 |
| Revlimid | 15 | $165,155 | $11,010 |
| Procrit | 19 | $70,989 | $3,736 |
| Exemestane | 54 | $11,176 | $207 |
| Letrozole | 96 | $1,353 | $14 |
| Hydroxyurea | 36 | $1,121 | $31 |
| Anastrozole | 122 | $1,118 | $9 |
| Bicalutamide | 34 | $816 | $24 |
| Hydrocodone-Acetaminophen | 25 | $703 | $28 |
| Dexamethasone | 32 | $415 | $13 |
| Ondansetron | 23 | $283 | $12 |
| Levothyroxine | 16 | $249 | $16 |
| Warfarin | 11 | $248 | $23 |
| Prednisone | 22 | $212 | $10 |
| Omeprazole | 14 | $82 | $6 |
2015: 25 drugs
| Revlimid | 18 | $167,000 | $9,278 |
| Zytiga | 18 | $139,923 | $7,773 |
| Xtandi | 15 | $129,202 | $8,613 |
| Procrit | 22 | $79,245 | $3,602 |
| Exemestane | 25 | $6,198 | $248 |
| Oxycodone | 38 | $3,142 | $83 |
| Hydrocodone-Acetaminophen | 42 | $1,842 | $44 |
| Morphine Sulfate Er | 29 | $1,834 | $63 |
| Fentanyl | 21 | $1,637 | $78 |
| Letrozole | 83 | $926 | $11 |
| Hydroxyurea | 32 | $883 | $28 |
| Anastrozole | 70 | $687 | $10 |
| Dexamethasone | 28 | $512 | $18 |
| Gabapentin | 30 | $409 | $14 |
| Mirtazapine | 30 | $407 | $14 |
| Prednisone | 30 | $294 | $10 |
| Warfarin | 17 | $287 | $17 |
| Ondansetron | 20 | $229 | $11 |
| Levothyroxine | 14 | $199 | $14 |
| Bicalutamide | 11 | $164 | $15 |
| Omeprazole | 21 | $152 | $7 |
| Lorazepam | 26 | $130 | $5 |
| Pantoprazole | 12 | $122 | $10 |
| Zolpidem | 19 | $88 | $5 |
| Spironolactone | 11 | $63 | $6 |
2014: 8 drugs
| Fentanyl | 17 | $1,779 | $105 |
| Oxycodone | 21 | $1,574 | $75 |
| Hydrocodone-Acetaminophen | 16 | $816 | $51 |
| Morphine Sulfate Er | 12 | $618 | $51 |
| Ondansetron | 14 | $430 | $31 |
| Metoprolol | 12 | $366 | $30 |
| Dexamethasone | 16 | $237 | $15 |
| Anastrozole | 11 | $164 | $15 |
Money from drug and device companies
$1,461 in 2025
| 2025 | 28 | 55 | None | $1,461 |
| 2024 | 20 | 43 | None | $1,119 |
| 2023 | 25 | 82 | None | $2,234 |
| 2022 | 22 | 72 | $430 | $2,167 |
| 2021 | 25 | 98 | None | $2,325 |
| 2020 | 27 | 127 | None | $2,900 |
| 2019 | 23 | 71 | $3,225 | $4,652 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Lynparza | $312 | 12 payments
|
| GlaxoSmithKline | Jemperli | $153 | 3 payments
|
| Dompe US | Oxervate | $125 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Reblozyl | $117 | 3 payments
|
| Novartis Pharmaceuticals | Fabhalta | $106 | 4 payments
|
| Janssen Biotech | Erleada | $82 | 3 payments
|
See all 52 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-18 | None | $22 |
| Servier Pharmaceuticals | Meals · 2025-12-09 | Voranigo | $32 |
| BeOne Medicines USA | Meals · 2025-11-25 | Tevimbra | $30 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-11-20 | Nubeqa | $15 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-11 | Reblozyl | $80 |
| Sobi | Meals · 2025-10-30 | Vonjo | $27 |
| Novartis Pharmaceuticals | Meals · 2025-10-23 | Fabhalta | $32 |
| Janssen Biotech | Meals · 2025-10-16 | Rybrevant | $22 |
| Aveo Pharmaceuticals | Meals · 2025-10-15 | Fotivda | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-14 | None | $26 |
| Progenics Pharmaceuticals | Meals · 2025-10-10 | Pylarify | $20 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-03 | None | $33 |
| Merck Sharp & Dohme | Meals · 2025-09-24 | Keytruda | $17 |
| Astellas Pharma US | Meals · 2025-09-16 | Vyloy | $14 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-12 | Enhertu | $27 |
| GlaxoSmithKline | Meals · 2025-09-11 | Jemperli | $14 |
| GlaxoSmithKline | Meals · 2025-09-10 | Jemperli | $118 |
| Novartis Pharmaceuticals | Meals · 2025-09-04 | Pluvicto | $25 |
| Genentech USA | Meals · 2025-09-02 | Polivy | $32 |
| Celgene | Meals · 2025-08-28 | Reblozyl | $20 |
| Daiichi Sankyo | Meals · 2025-08-26 | Enhertu | $20 |
| Novartis Pharmaceuticals | Meals · 2025-08-14 | Fabhalta | $22 |
| Genzyme | Meals · 2025-08-08 | Ayvakit | $23 |
| GlaxoSmithKline | Meals · 2025-08-07 | Ojjaara | $20 |
| Geron | Meals · 2025-08-05 | Rytelo | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-31 | Tagrisso | $21 |
| Incyte | Meals · 2025-07-23 | Monjuvi | $19 |
| Dompe US | Meals · 2025-07-17 | Oxervate | $125 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-11 | Opdivo | $23 |
| Lilly USA | Meals · 2025-07-09 | Verzenio | $32 |
| Janssen Biotech | Meals · 2025-06-13 | Erleada | $29 |
| Legend Biotech USA | Meals · 2025-06-12 | Carvykti | $16 |
| Daiichi Sankyo | Meals · 2025-05-30 | Enhertu | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-28 | None | $33 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-22 | Imfinzi | $26 |
| Pfizer | Meals · 2025-05-16 | Ibrance | $19 |
| Novartis Pharmaceuticals | Meals · 2025-05-13 | Lutathera | $28 |
| Progenics Pharmaceuticals | Meals · 2025-05-09 | Pylarify | $19 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-25 | Tagrisso | $25 |
| Aveo Pharmaceuticals | Meals · 2025-04-24 | Fotivda | $23 |
| Janssen Biotech | Meals · 2025-04-21 | Erleada | $31 |
| Kite Pharma | Meals · 2025-03-22 | Yescarta | $23 |
| Regeneron Healthcare Solutions | Meals · 2025-03-14 | Libtayo | $15 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-10 | None | $14 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-27 | Lynparza | $33 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-21 | Imfinzi | $14 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-21 | Enhertu | $15 |
| Eisai | Meals · 2025-02-03 | Lenvima | $14 |
| Pharmacosmos Therapeutics | Meals · 2025-01-29 | Monoferric | $25 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-24 | Lynparza | $38 |
| Novocure | Meals · 2025-01-14 | Optune Lua (Novottf-200t) | $19 |
| Lilly USA | Meals · 2025-01-10 | Verzenio | $19 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,119
| Janssen Biotech | Erleada | $247 | 11 payments
|
| Daiichi Sankyo | Enhertu | $117 | 1 payment
|
| Pfizer | Ibrance | $108 | 4 payments
|
| Novartis Pharmaceuticals | Pluvicto | $77 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $69 | 3 payments
|
| Exelixis | Cabometyx | $66 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $56 | 2 payments
|
| Progenics Pharmaceuticals | Pylarify | $53 | 2 payments
|
| Astellas Pharma US | Xtandi | $50 | 2 payments
|
| Eisai | Lenvima | $48 | 2 payments
|
| Rigel Pharmaceuticals | Rezlidhia | $35 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $30 | 1 payment
|
| Lilly USA | Verzenio | $27 | 1 payment
|
| Abbvie | Imbruvica | $24 | 1 payment
|
| Coherus Biosciences | Udenyca | $23 | 1 payment
|
| Taiho Oncology | Lonsurf | $21 | 1 payment
|
| Incyte | Jakafi | $19 | 1 payment
|
| Celgene | Reblozyl | $18 | 1 payment
|
| BeiGene USA | Tevimbra | $17 | 1 payment
|
| Servier Pharmaceuticals | Idhifa | $16 | 1 payment
|
2023: $2,234
| Seagen | Adcetris | $289 | 6 payments
|
| Janssen Biotech | Erleada | $283 | 8 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $207 | 5 payments
|
| Amgen | Nplate | $180 | 7 payments
|
| Progenics Pharmaceuticals | Pylarify | $158 | 4 payments
|
| Exelixis | Cabometyx | $154 | 4 payments
|
| Lilly USA | Verzenio | $151 | 5 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $134 | 6 payments
|
| PharmaEssentia USA | Besremi | $78 | 3 payments
|
| AVEO Pharmaceuticals | Fotivda | $72 | 4 payments
|
| Pfizer | Ibrance | $70 | 3 payments
|
| Eisai | Lenvima | $70 | 3 payments
|
| Celgene | Reblozyl | $60 | 3 payments
|
| ADC Therapeutics America | None | $44 | 2 payments
|
| Rigel Pharmaceuticals | Rezlidhia | $43 | 3 payments
|
| Novartis Pharmaceuticals | None | $40 | 2 payments
|
| Amneal Pharmaceuticals | Avastin | $30 | 1 payment
|
| Sumitomo Pharma America | Orgovyx | $27 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $25 | 1 payment
|
| Coherus Biosciences | Udenyca | $25 | 1 payment
|
| Kite Pharma | Yescarta | $22 | 1 payment
|
| Astellas Pharma US | Xtandi | $22 | 1 payment
|
| Accord Healthcare | Camcevi | $19 | 1 payment
|
| CTI BioPharma | Vonjo | $16 | 1 payment
|
| Pharmacosmos Therapeutics | Monoferric | $16 | 1 payment
|
2022: $2,167
| GlaxoSmithKline | Blenrep | $496 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $301 | 10 payments
|
| Sun Pharmaceutical Industries | Cequa | $195 | 1 payment
|
| Lilly USA | Verzenio | $159 | 6 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $141 | 9 payments
|
| Horizon Therapeutics plc | Tepezza | $117 | 1 payment
|
| Seagen | Adcetris | $98 | 4 payments
|
| Celgene | Reblozyl | $75 | 4 payments
|
| Rigel Pharmaceuticals | Tavalisse | $72 | 4 payments
|
| Amgen | Evenity | $71 | 3 payments
|
| Novartis Pharmaceuticals | Kisqali | $70 | 3 payments
|
| Janssen Biotech | Erleada | $64 | 4 payments
|
| AVEO Pharmaceuticals | Fotivda | $57 | 3 payments
|
| Acrotech Biopharma | Beleodaq | $52 | 4 payments
|
| Kite Pharma | None | $42 | 2 payments
|
| Exelixis | Cabometyx | $27 | 1 payment
|
| Progenics Pharmaceuticals | Pylarify | $27 | 1 payment
|
| Astellas Pharma US | Padcev | $24 | 1 payment
|
| Eisai | Lenvima | $23 | 1 payment
|
| Incyte | Monjuvi | $20 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $20 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $16 | 1 payment
|
2021: $2,325
| Seagen | Adcetris | $345 | 9 payments
|
| Pfizer | Ibrance | $275 | 12 payments
|
| Amgen | Evenity | $197 | 5 payments
|
| Janssen Biotech | Erleada | $171 | 8 payments
|
| Merck Sharp & Dohme | Keytruda | $135 | 6 payments
|
| Novartis Pharmaceuticals | Mekinist | $132 | 7 payments
|
| GlaxoSmithKline | Blenrep | $125 | 5 payments
|
| Kite Pharma | None | $115 | 5 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $114 | 6 payments
|
| Exelixis | Cabometyx | $87 | 4 payments
|
| Lilly USA | Verzenio | $85 | 3 payments
|
| Daiichi Sankyo | Enhertu | $79 | 4 payments
|
| Celgene | Reblozyl | $77 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $69 | 4 payments
|
| Karyopharm Therapeutics | Xpovio | $60 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Stivarga | $46 | 2 payments
|
| Incyte | Monjuvi | $46 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | None | $39 | 3 payments
|
| Array Biopharma | Braftovi | $24 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $21 | 1 payment
|
| EMD Serono | None | $18 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Cosela | $18 | 1 payment
|
| Servier Pharmaceuticals | Tibsovo | $17 | 1 payment
|
| Eisai | Lenvima | $16 | 1 payment
|
| Acrotech Biopharma | Beleodaq | $12 | 1 payment
|
2020: $2,900
| Pfizer | Ibrance | $482 | 21 payments
|
| Seagen | Adcetris | $283 | 10 payments
|
| Amgen | Kyprolis | $280 | 6 payments
|
| Janssen Biotech | Erleada | $229 | 8 payments
|
| E.R. Squibb & Sons L.L.C. | Inrebic | $199 | 13 payments
|
| GlaxoSmithKline | Zejula | $153 | 11 payments
|
| Allergan | None | $125 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Calquence | $123 | 6 payments
|
| Merck Sharp & Dohme | Keytruda | $118 | 6 payments
|
| Bayer HealthCare Pharmaceuticals | Stivarga | $118 | 5 payments
|
| Takeda Pharmaceuticals U.S.A. | Alunbrig | $81 | 4 payments
|
| Daiichi Sankyo | Enhertu | $80 | 4 payments
|
| Astellas Pharma US | Padcev | $78 | 4 payments
|
| Incyte | Jakafi | $77 | 4 payments
|
| Novartis Pharmaceuticals | Tasigna | $68 | 3 payments
|
| Genzyme | Sarclisa | $65 | 3 payments
|
| Celgene | Pomalyst | $60 | 3 payments
|
| Mylan Institutional | Ogivri | $43 | 2 payments
|
| Lilly USA | Erbitux | $42 | 2 payments
|
| Kite Pharma | None | $41 | 2 payments
|
| Dova Pharmaceuticals | Doptelet | $36 | 2 payments
|
| Exelixis | Cabometyx | $33 | 2 payments
|
| Blueprint Medicines | Gavreto | $23 | 1 payment
|
| Eisai | Lenvima | $21 | 1 payment
|
| AbbVie | Venclexta | $18 | 1 payment
|
| Janssen Scientific Affairs | Zytiga | $15 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $12 | 1 payment
|
2019: $4,652
| AstraZeneca Pharmaceuticals LP | Tagrisso | $2,280 | 4 payments
|
| Janssen Biotech | Darzalex | $1,307 | 11 payments
|
| Pfizer | Ibrance | $205 | 20 payments
|
| Novartis Pharmaceuticals | Tasigna | $145 | 7 payments
|
| Agios Pharmaceuticals | Tibsovo | $85 | 1 payment
|
| Sirtex Medical | Sir-Spheres Microspheres | $78 | 1 payment
|
| EMD Serono | Bavencio | $66 | 3 payments
|
| Amgen | Kyprolis | $64 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $56 | 3 payments
|
| Octapharma USA | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) | $49 | 1 payment
|
| Tesaro | Zejula | $42 | 2 payments
|
| Daiichi Sankyo | Injectafer | $42 | 2 payments
|
| Genzyme | Elitek | $36 | 2 payments
|
| Rigel Pharmaceuticals | Tavalisse | $32 | 2 payments
|
| Seattle Genetics | Adcetris | $25 | 1 payment
|
| Shire North American Group | Advate | $22 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Xofigo | $20 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $20 | 1 payment
|
| Exelixis | Cabometyx | $19 | 1 payment
|
| Stemline Therapeutics | Elzonris | $17 | 1 payment
|
| Incyte | Jakafi | $16 | 1 payment
|
| AMAG Pharmaceuticals | Feraheme | $15 | 1 payment
|
| Astellas Pharma US | Xtandi | $13 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| TESARO, Inc. · A Phase III Trial of Niraparib Versus Physician'S Choice in Her2 Negative, Germline Brca Mutation-Positive Breast Cancer Patients Bravo · 2019 | Their institution | $6,500 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1114169323
- Licence
- CA A66600California A66600: Current · expires 2028-07-31
- Trained
- University of California, Geffen School of Medicine, 1997
- Group
- Sutter Coast Hospital · Phc-Las Cruces Inc · Las Cruces Physician Practices, LLC
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X); Internal medicine (207R00000X)
- Mailing address
- 9460 N Name Uno Ste 230, Gilroy, CA, 95020
- NPI first listed
- 2009-04-02
- NPI last updated
- 2022-08-03
- NPI record certified
- 2022-08-03
This is when the NPI record was last certified, not a medical board exam.